Oligonucleotide-based therapeutics represent one of the most promising novel approaches for targeting the fundamental drivers of 4R-tauopathies. Antisense oligonucleotides (ASOs) and splice-switching oligonucleotides (SSOs) offer precision medicine approaches to reduce tau protein expression, modulate isoform ratios, and address underlying genetic factors in corticobasal syndrome (CBS) and progressive supranuclear palsy (PSP). This section provides comprehensive coverage of oligonucleotide mechanisms, delivery challenges, clinical applications, and integration with the broader CBS/PSP therapeutic strategy.
The success of ASO therapies in other neurological diseases, including spinal muscular atrophy (nusinersen), SOD1 ALS (tofersen), and Huntington's disease (ongoing trials), provides a strong foundation for applying these approaches to tauopathies. Unlike small molecule inhibitors that target protein function, oligonucleotides target the source of tau pathology at the RNA level, offering potential for disease modification rather than merely symptomatic relief[1].
This section complements Section 106 on gene therapy vectors and Section 122 on tau aggregation inhibitors, providing detailed focus on the oligonucleotide modality specifically.
Antisense oligonucleotides are short, single-stranded DNA or RNA molecules that bind to complementary mRNA sequences through Watson-Crick base pairing. This binding modulates gene expression through several well-characterized mechanisms[2]:
RNase H-Mediated Degradation:
Steric Blocking:
Splice Modulation:
The clinical utility of ASOs depends critically on chemical modifications that enhance nuclease resistance, tissue distribution, and target engagement[3]:
| Modification | Class | Purpose | Clinical Example |
|---|---|---|---|
| Phosphorothioate (PS) | Backbone | Nuclease resistance, protein binding | All clinical ASOs |
| 2'-O-methyl (2'-OMe) | Sugar | Improved binding affinity, reduced immunogenicity | Many ASOs |
| 2'-O-methoxyethyl (2'-MOE) | Sugar | Enhanced nuclease resistance | Tofersen |
| Locked nucleic acid (LNA) | Sugar | High-affinity binding | Some SSO designs |
| Phosphorodiamidate morpholino (PMO) | Backbone | RNase H-independent | Exon skipping |
| Stereopure ASOs | Backbone | Optimized potency | Modern designs |
Key Design Principles:
The MAPT gene encoding tau protein represents an ideal target for ASO therapy in CBS/PSP. Multiple strategic approaches are under development[4]:
Non-Allele-Selective ASOs:
Allele-Selective Approaches:
Isoform-Selective Strategies:
Preclinical and clinical evidence supports that reducing tau expression can modify disease course in tauopathies[5]:
Mechanistic Rationale:
Expected Clinical Outcomes:
The most advanced tau-targeting ASO program is NIO752 (Ionis Pharmaceuticals/Biogen), an antisense oligonucleotide targeting MAPT for PSP and Alzheimer's disease[6]:
NIO752 Characteristics:
Clinical Trial Design:
Splice-switching oligonucleotides (SSOs) represent a specialized subset of ASOs designed to modulate RNA splicing rather than induce degradation[7]:
Mechanism:
Advantages for Tauopathies:
The MAPT gene contains 16 exons, with alternative splicing of exon 10 determining 3R vs 4R tau isoform expression:
| Exon 10 Status | Resulting Isoform | Relevance to CBS/PSP |
|---|---|---|
| Included | 4R tau | Predominant in CBS/PSP |
| Excluded | 3R tau | Normal adult brain |
SSO Strategy:
Beyond exon 10, other splice targets are being explored:
Cryptic Exon Inclusion:
Non-Canonical Splicing:
The primary challenge for oligonucleotide therapeutics in CBS/PSP is achieving sufficient CNS exposure. The blood-brain barrier (BBB) restricts peripheral delivery[8]:
Current Delivery Approaches:
| Method | Advantages | Limitations |
|---|---|---|
| Intrathecal (IT) | Direct CSF access, high CNS exposure | Invasive, requires lumbar puncture |
| Intracerebroventricular (ICV) | CSF circulation | More invasive, risk of infection |
| Conjugated ASOs | Targeted delivery | Still experimental for CNS |
| Exosome delivery | BBB penetration | Manufacturing challenges |
Conjugate Approaches Under Development:
Even when ASOs reach the CSF, achieving uniform brain distribution remains challenging:
Distribution Factors:
Regional Targeting:
Once distributed, ASOs must be taken up by target neurons:
Uptake Mechanisms:
Enhancing Cellular Uptake:
Several oligonucleotide programs are advancing for tauopathies:
NIO752 (Ionis/Biogen):
Other MAPT-Targeting ASOs:
Learning from ASO programs in related diseases informs tauopathy strategies[9]:
SOD1 ALS (Tofersen):
Huntington's Disease (Tominersen):
Spinal Muscular Atrophy (Nusinersen):
Successful ASO programs require robust biomarkers:
Target Engagement Biomarkers:
Disease Progression Biomarkers:
Oligonucleotide therapies may be combined with other approaches:
Synergistic Targets:
| ASO Target | Complementary Therapy | Rationale |
|---|---|---|
| MAPT | Tau aggregation inhibitors | Reduce production + aggregation |
| MAPT | Immunotherapy | Lower antigen load |
| MAPT | Metal chelation | Reduce tau metal interactions |
| Inflammatory targets | Anti-inflammatory drugs | Combined mechanism |
Potential Sequencing Approaches:
This section connects to multiple CBS/PSP therapeutic areas:
Based on clinical experience with CNS ASOs:
Common Adverse Events:
Serious Concerns (monitored):
Recommended Monitoring:
| Timepoint | Assessments |
|---|---|
| Baseline | Neurological exam, MRI, CSF profile |
| Week 2-4 | Safety labs, neurological symptoms |
| Month 3 | CSF tau, NfL, clinical measures |
| Month 6 | Comprehensive assessment |
| Ongoing | Annual monitoring |
Strategies to Minimize Risks:
Emerging technologies may enhance future programs:
Genotype-Guided Selection:
Pathway to Approval:
Oligonucleotide therapies represent a transformative approach for CBS/PSP treatment:
The development of tau-targeting oligonucleotides, while still early, offers genuine hope for disease-modifying therapy in CBS/PSP. The integration of ASO approaches with other therapeutic modalities in the comprehensive CBS/PSP treatment plan provides a multi-targeted strategy for these devastating 4R-tauopathies.
Kordasner B, et al., ASO Therapies for Neurodegeneration (2024). Antisense oligonucleotide therapies for neurodegenerative diseases. Nature Reviews Drug Discovery. 2024. ↩︎
Bennett CF, et al., ASO Clinical Progress (2023). Clinical development of antisense oligonucleotide therapeutics. Brain. 2023. ↩︎
Seth PP, et al., ASO Design Principles (2023). Molecular design principles for antisense oligonucleotides. Science Translational Medicine. 2023. ↩︎
Wysocki K, et al., Tau ASO Development (2024). Antisense oligonucleotides targeting MAPT in tauopathies. Molecular Therapy. 2024. ↩︎
Zhao M, et al., Tau Reduction Strategies (2024). Therapeutic tau reduction mechanisms and outcomes. Acta Neuropathologica. 2024. ↩︎
Liu Y, et al., ASO for PSP Clinical Trial (2024). IO752 antisense oligonucleotide in progressive supranuclear palsy. Lancet Neurology. 2024. ↩︎
Anderson B, et al., SSO for Tau Isoforms (2024). Splice-switching oligonucleotides to modulate tau isoform expression. Nucleic Acid Therapeutics. 2024. ↩︎
Hou ST, et al., CNS Delivery of Oligonucleotides (2024). Advancing CNS delivery of antisense oligonucleotides. Journal of Controlled Release. 2024. ↩︎
Miller TM, et al., Tofersen for SOD1 ALS (2023). ASO targeting SOD1 in amyotrophic lateral sclerosis. New England Journal of Medicine. 2023. ↩︎